Publication | Open Access

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index

Serum-soluble Interleukin-2 ReceptorLymphoid NeoplasiaAutoimmune DiseaseMedicineImmunodeficienciesMalignant Blood DisorderImmunologyPathologyS LymphomaImmune SurveillanceAutoimmunityInternational Prognostic IndexAdult T-cell Leukemia-lymphomaImmunotherapyOncologyCancer Research